Implementation of a Person-Centered and Integrated Care Pathway for Hypertension

ConditionHypertension
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRegion Stockholm

About this trial

The aim is to investigate whether information and educational initiatives on the Swedish national care pathway for hypertension, directed at primary care centers, lead to an increase in the proportion of patients achieving target blood pressure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Crossover

Treatments tested in this trial

  • Educational intervention for doctors and nurses

    Other intervention

    Educational intervention for doctors and nurses. Information and educational initiatives on the national care pathway for hypertension, including specific recommendations regarding treatment and the use of digital support tools. The intervention consists of in-person lectures by a physician educator, combined with an information package for physicians, nurses and patients. This includes standardised treatment algorithms with early combination therapy. Educational material will be made available electronically. Primary care centers will be provided with tools for continuous monitoring of their performance.

Treatment groups

120,000 Participants
are divided into 2 treatment groups
Group A: InterventionExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Change from baseline in the proportion of patients with blood pressure <130/<80 mmHg

Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals whose last recorded blood pressure was below the target according to the person-centered and integrated care pathway (PSVF) for hypertension (\<130/\<80 mmHg), irrespective of measurement method (office, home, or ambulatory blood pressure monitoring). The outcome is assessed in each 6-month interval, and the primary effect measure is the average effect over the first 12 months after each center's scheduled crossover.

Time frame
6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods

Secondary outcomes

1

Change from baseline in the proportion of patients with their blood pressure measured

Proportion of patients with a diagnosis of hypertension who, in each 6-month interval had their blood pressure measured

Time frame
6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
2

Change from baseline in the proportion of patients who were dispensed statin therapy

Proportion of patients with a diagnosis of hypertension who were dispensed statin therapy

Time frame
6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
3

Change from baseline in the proportion of patients who achieved an office blood pressure <140/<90 mmHg, a home blood pressure <135/<85 mmHg, or an ambulatory blood pressure <135/<85 mmHg

Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals who achieved an office blood pressure \<140/\<90 mmHg, a home blood pressure \<135/\<85 mmHg, or an ambulatory blood pressure \<135/\<85 mmHg. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover.

Time frame
6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
4

Change from baseline in the proportion of patients who were dispensed combination therapy with antihypertensive agents

Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more)

Time frame
6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods

Other outcomes

1

Adverse drug reactions related to antihypertensive medication

Safety outcome. Adverse drug reactions related to antihypertensive medication: acute kidney injury, hypotension or syncope, orthostatic hypotension, and fall injury. Based on hospitalizations with relevant ICD-10 codes.

Time frame
First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover
2

Myocardial infarction and stroke

Hypertension-related complications: myocardial infarction and stroke

Time frame
First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover
3

All-cause mortality

All-cause mortality

Time frame
First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Region Stockholm

Lead sponsor

Karolinska Institutet

Collaborator

This trial is not recruiting at the moment. You can still explore other options: